Trial Profile
Alemtuzumab or rituximab induction in ABO-incompatible kidney transplantation.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2018
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 15 Oct 2015 New trial record